{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T19:29:42Z","timestamp":1757618982603,"version":"3.44.0"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,28]],"date-time":"2025-07-28T00:00:00Z","timestamp":1753660800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,28]],"date-time":"2025-07-28T00:00:00Z","timestamp":1753660800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["EJNMMI Rep."],"DOI":"10.1186\/s41824-025-00262-8","type":"journal-article","created":{"date-parts":[[2025,7,27]],"date-time":"2025-07-27T22:02:24Z","timestamp":1753653744000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["First-in-human experience of radiopharmaceutical therapy with [177Lu]Lu-DOTATATE in patients with advanced multiple myeloma"],"prefix":"10.1186","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6674-9493","authenticated-orcid":false,"given":"Wendy","family":"Delbart","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie","family":"Vercruyssen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rachele","family":"Danieli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cl\u00e9mentine","family":"Marin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Z\u00e9na","family":"Wimana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nathalie","family":"Meuleman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick","family":"Flamen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erwin","family":"Woff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ioannis","family":"Karfis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,7,28]]},"reference":[{"key":"262_CR1","doi-asserted-by":"crossref","unstructured":"Langbein T, Weber WA, Eiber M (2019) Future of Theranostics: An Outlook on Precision Oncology in Nuclear Medicine. J Nucl Med. 9 janv.;60(Supplement 2):13S-19S","DOI":"10.2967\/jnumed.118.220566"},{"key":"262_CR2","doi-asserted-by":"crossref","unstructured":"Strosberg J, El-Haddad G, Wolin E, Hendifar A, Yao J, Chasen B et al (2017) Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors. N Engl J Med. 12 janv.;376(2):125\u201335","DOI":"10.1056\/NEJMoa1607427"},{"key":"262_CR3","doi-asserted-by":"crossref","unstructured":"Sartor O, de Bono J, Chi KN, Fizazi K, Herrmann K, Rahbar K et al (sept 2021) Lutetium-177\u2013PSMA-617 for metastatic Castration-Resistant prostate Cancer. N Engl J Med 16(12):1091\u20131103","DOI":"10.1056\/NEJMoa2107322"},{"issue":"3","key":"262_CR4","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1159\/000475526","volume":"105","author":"RJ Hicks","year":"2017","unstructured":"Hicks RJ, Kwekkeboom DJ, Krenning E, Bodei L, Grozinsky-Glasberg S, Arnold R et al (2017) ENETS consensus guidelines for the standards of care in neuroendocrine neoplasms: peptide receptor radionuclide therapy with radiolabelled somatostatin analogues. Neuroendocrinol 13 Avr 105(3):295\u2013309","journal-title":"Neuroendocrinol 13 Avr"},{"issue":"9","key":"262_CR5","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1001\/jamaoncol.2018.2128","volume":"4","author":"AJ Cowan","year":"2018","unstructured":"Cowan AJ, Allen C, Barac A, Basaleem H, Bensenor I, Curado MP et al (2018) Global burden of multiple myeloma. JAMA Oncol Sept 4(9):1221\u20131227","journal-title":"JAMA Oncol Sept"},{"issue":"4","key":"262_CR6","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1097\/RLU.0b013e31828e9722","volume":"39","author":"P Sharma","year":"2014","unstructured":"Sharma P, Dhull VS, Suman SKC, Bal C, Malhotra A, Kumar R (2014) 68Ga-DOTANOC somatostatin receptor PET-CT imaging in multiple myeloma. Clin Nucl Med Avr 39(4):374\u2013375","journal-title":"Clin Nucl Med Avr"},{"issue":"1","key":"262_CR7","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1007\/s00259-009-1199-5","volume":"37","author":"A Agool","year":"2010","unstructured":"Agool A, Slart RHJA, Dierckx RAJO, Kluin PM, Visser L, Jager PL et al (2010) Somatostatin receptor scintigraphy might be useful for detecting skeleton abnormalities in patients with multiple myeloma and plasmacytoma. Eur J Nucl Med Mol Imaging Janv 37(1):124\u2013130","journal-title":"Eur J Nucl Med Mol Imaging Janv"},{"issue":"1","key":"262_CR8","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1097\/MNM.0000000000000610","volume":"38","author":"K Sonmezoglu","year":"2017","unstructured":"Sonmezoglu K, Vatankulu B, Elverdi T, Akyel R, Erkan ME, Halac M et al (2017) The role of 68Ga-DOTA-TATE PET\/CT scanning in the evaluation of patients with multiple myeloma: preliminary results. Nucl Med Commun Janv 38(1):76\u201383","journal-title":"Nucl Med Commun Janv"},{"key":"262_CR9","doi-asserted-by":"crossref","unstructured":"EANM\u201924 Abstract Book Congress Oct 19\u201323 (2024) Eur J Nucl Med Mol Imaging. 1 sept 2024;51(1):1\u20131026","DOI":"10.1007\/s00259-024-06838-z"},{"key":"262_CR10","doi-asserted-by":"crossref","unstructured":"Mileva M, Marin G, Levillain H, Artigas C, Van Bogaert C, Marin C et al (2024) Prediction of 177Lu-DOTATATE PRRT Outcome Using Multimodality Imaging in Patients with Gastroenteropancreatic Neuroendocrine Tumors: Results from a Prospective Phase II LUMEN Study. J Nucl Med Off Publ Soc Nucl Med. 1 f\u00e9vr.;65(2):236\u201344","DOI":"10.2967\/jnumed.123.265987"},{"key":"262_CR11","first-page":"41","volume":"56","author":"G Marin","year":"2018","unstructured":"Marin G, Vanderlinden B, Karfis I, Guiot T, Wimana Z, Reynaert N et al (2018) A dosimetry procedure for organs-at-risk in 177Lu peptide receptor radionuclide therapy of patients with neuroendocrine tumours. Phys Med PM Int J Devoted Appl Phys Med Biol Off J Ital Assoc Biomed Phys AIFB D\u00e9c 56:41\u201349","journal-title":"Phys Med PM Int J Devoted Appl Phys Med Biol Off J Ital Assoc Biomed Phys AIFB D\u00e9c"},{"issue":"10446","key":"262_CR12","doi-asserted-by":"publisher","first-page":"2807","DOI":"10.1016\/S0140-6736(24)00701-3","volume":"403","author":"S Singh","year":"2024","unstructured":"Singh S, Halperin D, Myrehaug S, Herrmann K, Pavel M, Kunz PL et al (2024) [177Lu]Lu-DOTA-TATE plus long-acting octreotide versus high\u2013dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2\u20133, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): an open-label, randomised, phase 3 study. Lancet Lond Engl 29 Juin 403(10446):2807\u20132817","journal-title":"Lancet Lond Engl 29 Juin"},{"issue":"2","key":"262_CR13","first-page":"248","volume":"57","author":"K Herrmann","year":"2016","unstructured":"Herrmann K, Schottelius M, Lapa C, Osl T, Poschenrieder A, H\u00e4nscheid H et al (2016) First-in-Human experience of CXCR4-Directed endoradiotherapy with 177Lu- and 90Y-Labeled pentixather in Advanced-Stage multiple myeloma with extensive Intra- and extramedullary disease. J Nucl Med Off Publ Soc Nucl Med F\u00e9vr 57(2):248\u2013251","journal-title":"J Nucl Med Off Publ Soc Nucl Med F\u00e9vr"},{"issue":"6","key":"262_CR14","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.7150\/thno.19050","volume":"7","author":"C Lapa","year":"2017","unstructured":"Lapa C, Herrmann K, Schirbel A, H\u00e4nscheid H, L\u00fcckerath K, Schottelius M et al (2017) CXCR4-directed endoradiotherapy induces high response rates in extramedullary relapsed multiple myeloma. Theranostics 7(6):1589\u20131597","journal-title":"Theranostics"},{"key":"262_CR15","doi-asserted-by":"crossref","unstructured":"Costa LJ, Cornell RF, Callander NS, Chhabra S, Liedtke M, Kansagra A et al Efficacy of treatments for patients with Triple-Class refractory (TCR) multiple myeloma (MM): benchmark for new agents utilizing Real-World data (RWD). Blood. 23 nov 2021;138:3786.","DOI":"10.1182\/blood-2021-144387"},{"key":"262_CR16","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.nucmedbio.2021.03.006","volume":"96\u201397","author":"W Delbart","year":"2021","unstructured":"Delbart W, Ghanem GE, Karfis I, Flamen P, Wimana Z (2021) Investigating intrinsic radiosensitivity biomarkers to peptide receptor radionuclide therapy with [177Lu]Lu-DOTATATE in a panel of cancer cell lines. Nucl Med Biol Juin 96\u201397:68\u201379","journal-title":"Nucl Med Biol Juin"}],"container-title":["EJNMMI Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41824-025-00262-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s41824-025-00262-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41824-025-00262-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T11:15:33Z","timestamp":1757243733000},"score":1,"resource":{"primary":{"URL":"https:\/\/ejhi.springeropen.com\/articles\/10.1186\/s41824-025-00262-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,28]]},"references-count":16,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["262"],"URL":"https:\/\/doi.org\/10.1186\/s41824-025-00262-8","relation":{},"ISSN":["3005-074X"],"issn-type":[{"type":"electronic","value":"3005-074X"}],"subject":[],"published":{"date-parts":[[2025,7,28]]},"assertion":[{"value":"1 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 August 2025","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors corrected a spelling in the Abstract.","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The treatment was approved by the local ethics committee of Jules Bordet Institute (CE3817 and CE3493). Written informed consent was obtained from both patients.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Both patients gave consent for the publication of their data.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"26"}}